ClinicalTrials.gg

Program

RPX7009

Also written as “RPX7009 and RPX2014”, “Meropenem plus vaborbactam” and “Combination RPX7009 and RPX2014”.

Its studies are mostly in Bacterial Infections · Renal Insufficiency, led by 2 companies.

Furthest: phase 2, since Dec 13, 20126 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis50 open or runningphase 1since Dec 13, 2012Dec 13, 2012none ahead
Menarini Group11 open or runningphase 2since Feb 3, 2025Feb 3, 2025Oct 2027phase 2 · NCT06828848

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2012First study: phase 1 study in Bacterial InfectionsNew to NovartisNovartis · NCT01751269 · 80 enrolled · Australia
  2. Jan 16, 2013Phase 1 study in Bacterial InfectionsNovartis · NCT01772836 · 30 enrolled · Australia
  3. Jul 9, 2013Phase 1 study in Bacterial InfectionsNovartis · NCT01897779 · 94 enrolled · Australia
  4. Dec 10, 2013Phase 1 study in Subjects With Varying Degrees of Renal Insufficiency andNovartis · NCT02020434 · 32 enrolled · United States
  5. Feb 14, 2014Phase 1 study in Healthy SubjectsNovartis · NCT02073812 · 26 enrolled · United States
  6. Feb 3, 2025Menarini Group's first study: phase 2 study in Gram Negative InfectionsNew to Menarini GroupMenarini Group · NCT06828848 · 44 planned · Czechia, France, Italy and more
  7. Oct 7, 2026Primary completion moved from 2026-07 to 2027-10Date moved laterphase 2 · +15 months · NCT06828848

Ahead

  1. Oct 2027Primary completion: phase 2 study in Gram Negative InfectionsMenarini Group · NCT06828848

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Carbepenem-hydrolyzing beta-lactamase KPC inhibitor”ChEMBL 37, by rule

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06828848Gram Negative Infections · Czechia, France, Italy and more2RecruitingMenarini GroupOct 202744
NCT02073812Healthy Subjects · United States1CompletedNovartisApr 201426
NCT02020434Subjects With Varying Degrees of Renal Insufficiency and · United States1CompletedNovartisSep 201432
NCT01897779Bacterial Infections · Australia1CompletedNovartisFeb 201494
NCT01772836Bacterial Infections · Australia1CompletedNovartisMar 201330
NCT01751269Bacterial Infections · Australia1CompletedNovartisJul 201380

How it is read

Names in the registry

  • “RPX7009”, 3 entries
  • “RPX7009 and RPX2014”, 2 entries
  • “Meropenem plus vaborbactam”, 1 entry
  • “Combination RPX7009 and RPX2014”, 1 entry

Codes read as this program: RPX7009.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.